Supply Chain

Recall activity for pharmaceutical products rose 35 percent in the second quarter of 2016 to their highest level since the third quarter of 2014, according to a new Recall Index report. It also found that medical device recall activity increased…

Facing large scrutiny for the high price of its EpiPen medication, Mylan promised Thursday to lower the cost patients must pay for the life-saving injection, reported The Wall Street Journal.

Oak Brook, Ill.-based Medtronic acquired medical device manufacturer HeartWare International for $1.1 billion, according to Nasdaq.

 The American Medical Association joined consumers and a handful of senators in scrutinizing Mylan's extreme price hikes for its life-saving EpiPen injection.

The Food and Drug Administration granted priority review status to Clovis Oncology's experimental cancer drug.

Starting September 24, the Food and Drug Administration will require all Class II devices to be labeled with unique device identifiers.

Manufacturers associated with the EpiPen device have drawn heavy criticism from consumers and lawmakers, but it's not the only lifesaving drug on the market experiencing soaring costs. Insulin prices have risen to nearly $400 a month in some cases, roughly…

Mylan's life-saving EpiPen injection device is not the only medication in the company's portfolio that has seen large price spikes, reports NBC News.

Senator Joe Manchin's (D-W.Va.) ties to the congressional scrutiny surrounding the skyrocketing price of EpiPens runs deeper than just politics. His daughter, Heather Bresch, is CEO of Mylan, the company behind the epinephrine injection, reports The Washington Post.

Getting your master's degree in global sourcing